Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 in Sarcopenia Treatment
Details : LPCN 1148 comprises testosterone dodecanoate, a unique androgen receptor agonist. It is being investigated for treatment for sarcopenia in patients with decompensated cirrhosis.
Product Name : LPCN 1148
Product Type : Steroid
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Testosterone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Reports Positive Week 52 Results from LPCN 1148 Phase 2 Study
Details : LPCN 1148 is a novel prodrug of an androgen receptor agonist, designed to improve liver and muscle function, enhance quality of life before liver transplant, and reduce hospital admissions.
Product Name : LPCN 1148
Product Type : Steroid
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
Details : LPCN 1148 is an oral prodrug of bioidentical testosterone being developed in Phase 2 clinical study for the management of symptoms associated with cirrhosis.
Product Name : LPCN 1148
Product Type : Steroid
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD...
Product Name : Lybrido
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2023
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
Details : LPCN 1148 is a novel prodrug of androgen receptor agonist for oral administration with compelling multi modal action to improve liver and muscle function, resulting in improved quality of life while awaiting liver transplant, decreased hospital admission...
Product Name : LPCN 1148
Product Type : Steroid
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : Natesto
Product Type : Hormone
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Granted US Patents Directed To CNS And Liver Programs
Details : Testosterone Dodecanoate is steroid hormone, company filed patent for treatment of variety of diseases, such as CNS, cancer, Liver, Lung, Kidney, cardiovascular disease and endocrine disorders.
Product Name : LPCN 1148
Product Type : Steroid
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.
Product Name : Lybrido
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
Details : Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.
Product Name : Natesto
Product Type : Hormone
Upfront Cash : Undisclosed
October 05, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Testosterone topical solution USP, 30 mg per pump actuation is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and hypogonadotropic hypogonadism.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 16, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable